{"F": {"ts_code": "US.MGTX", "name": "MeiraGTx Holdings", "mkt": "US", "ccy": "美元", "sw1": "生物技术", "sw2": "生物技术", "sw3": "", "ind": "生物技术", "fin_source": "futu", "market": "NASDAQ", "list_date": "20180608", "is_fin": false, "roles": {"fin": false, "commodity": false, "precious": false, "regulated": false, "hard": false, "growth": true}, "province": null, "main_business": "", "introduction": "", "close": 13.89, "pe_ttm": 15.965, "pb": 6.187, "dv_ttm": 0.0, "total_mv": 133403.721444, "trade_date": "20260904", "years": ["最近年报"], "multi_year": false, "period": "最近年报", "gm_series": [94.0], "rev_series": [0.8], "np_series": [-1.1], "roe_series": [-368.2], "rev_ttm": 0.8, "np_ttm": 0.8, "ocf_ttm": 0.1, "fcf_ttm": null, "fcf_yield": null, "ocf_yield": 1.0, "gm_median": 94.0, "gm_std": null, "gm_stab": null, "gm_chg_2022": null, "npm_median": -140.3, "roe_median": -368.2, "commodity": false, "hard_ratio": 36.2, "fix_assets": 0.9, "hard_note": "PP&E 毛额 × 0.5 近似净额", "goodwill_ratio": null, "pb_calc": null, "capex_dep": null, "interest_debt": null, "debt_ebitda": null, "ebitda": -0.9, "debt_ratio": 102.4, "debt_mv": null, "payout": 0.0, "div_years": 0, "rev_cagr3": null, "np_cagr3": null, "rev_yoy": 144.6, "np_yoy": 22.7, "np_vol": null, "loss_years": 0, "far_share": 69.0, "earn_yield": 6.3, "consensus_n": 0, "fwd_pe": null, "fwd_pe2": null, "fwd_g1": null, "fwd_g2": null, "peg": null, "consensus_disp": null, "mainbz": [], "ret_prev_year": null, "ret_prev2_year": null, "ret_pivot": null, "prev_year": "", "prev2_year": "", "ret_ytd": 74.7, "ret_20": 6.3, "ret_60": 52.0, "ret_120": 80.6, "ret_250": 85.9, "mdd_250": null, "vol_250": null, "pos_52w": 90.5, "eps": -1.42}, "S": {"duration": 33, "pricing": 79, "hard": 58, "bondness": 13}, "label": "成长兑现", "tags": [], "text": {"像什么": ["盈利在追估值:最新净利润同比 23%,PE TTM 16.0 倍,历史 PEG(PE ÷ 最新增速)0.70。", "经营现金流 0.1 亿(正),没有一致预期数据,风险在增速能否延续。"], "为什么(不)算钱的替代品": "硬资产占比 36%、毛利率 94.0% 两条都占,但所在行业(生物技术)不在硬资产名单里(医药/科技的固定资产是产能不是储量),按主标签看。", "加息期怎么走": "估值不靠远期故事,加息期比纯久期抗跌;风险在订单与增速,盯业绩不盯利率。", "四问": [["当前 FCF 能覆盖多少市值?", "经营现金流/市值 1.0%(futu 无资本开支,FCF 按经营现金流 × 0.7 近似)。极低或为负。"], ["能否每年提价而不掉量?", "毛利率最新年报 94.0%。能。"], ["资产重置成本随通胀涨吗?", "固定资产占总资产 36%。涨。"], ["估值里多少来自 5 年后的故事?", "按 PE 16.0 倍 粗算,约 69%(1 − 5/PE)。中等。"]], "价格行为": "近一年 86%,现价在 52 周高点的 90%;近 20 / 60 / 120 日 6% / 52% / 81%。", "行业对照": ["同富途行业「生物技术」593 家中位:PE 13.7 / 股息率 0.0% / 毛利率 80.5% / 固定资产占比 5% / 分红率 0%。", "MeiraGTx Holdings:PE 比行业中位高 2.3倍;股息率 与行业中位持平;毛利率 比行业中位高 13.5个百分点;固定资产占比 比行业中位高 30.9个百分点。"]}}